Takeda Pharmaceutical Co. $TAK Stock Holdings Increased by Russell Investments Group Ltd.

Russell Investments Group Ltd. raised its holdings in shares of Takeda Pharmaceutical Co. (NYSE:TAK) by 42.2% during the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 64,463 shares of the company’s stock after acquiring an additional 19,139 shares during the period. Russell Investments Group Ltd.’s holdings in Takeda Pharmaceutical were worth $959,000 as of its most recent SEC filing.

Several other hedge funds have also recently added to or reduced their stakes in the business. Entropy Technologies LP bought a new stake in Takeda Pharmaceutical during the 1st quarter valued at $156,000. Invesco Ltd. bought a new stake in Takeda Pharmaceutical during the 1st quarter valued at $743,000. Charles Schwab Investment Management Inc. raised its stake in Takeda Pharmaceutical by 22.7% during the 1st quarter. Charles Schwab Investment Management Inc. now owns 311,216 shares of the company’s stock valued at $4,628,000 after acquiring an additional 57,665 shares in the last quarter. Lester Murray Antman dba SimplyRich raised its stake in Takeda Pharmaceutical by 76.2% during the 1st quarter. Lester Murray Antman dba SimplyRich now owns 34,671 shares of the company’s stock valued at $515,000 after acquiring an additional 14,999 shares in the last quarter. Finally, ABC Arbitrage SA bought a new stake in Takeda Pharmaceutical during the 1st quarter valued at $4,994,000. Institutional investors own 9.17% of the company’s stock.

Wall Street Analyst Weigh In

Separately, Zacks Research downgraded Takeda Pharmaceutical from a “hold” rating to a “strong sell” rating in a research note on Thursday, August 21st. One investment analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Hold”.

Takeda Pharmaceutical Stock Up 0.1%

TAK opened at $14.99 on Friday. Takeda Pharmaceutical Co. has a one year low of $12.80 and a one year high of $15.56. The company has a debt-to-equity ratio of 0.60, a quick ratio of 0.59 and a current ratio of 1.16. The stock’s fifty day moving average is $14.81 and its 200-day moving average is $14.73. The company has a market capitalization of $47.68 billion, a PE ratio of 49.95 and a beta of 0.22.

Takeda Pharmaceutical (NYSE:TAK) last posted its quarterly earnings data on Wednesday, July 30th. The company reported $0.52 EPS for the quarter, topping analysts’ consensus estimates of $0.47 by $0.05. The company had revenue of $7.45 billion for the quarter, compared to the consensus estimate of $7.96 billion. Takeda Pharmaceutical had a return on equity of 10.50% and a net margin of 3.20%. Takeda Pharmaceutical has set its FY 2025 guidance at 3.360-3.360 EPS. On average, equities analysts predict that Takeda Pharmaceutical Co. will post 1.64 EPS for the current fiscal year.

Takeda Pharmaceutical Company Profile

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience.